repotrectinib   Click here for help

GtoPdb Ligand ID: 10316

Synonyms: Augtyro® | example 93 [US20170334929A1] | TPX-0005 | TPX0005
Approved drug PDB Ligand
repotrectinib is an approved drug (FDA (2023))
Compound class: Synthetic organic
Comment: Repotrectinib (TPX-0005) is a next-generation oral ROS1/NTRK/ALK inhibitor that was rationally designed to overcome tumour resistance due to acquired mutations in these kinases [3-4]. The chemical structure is claimed as example 93 in TP Therapeutics' patent US20170334929A1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 0
Topological polar surface area 80.55
Molecular weight 355.14
XLogP 3.08
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC1CNC(=O)c2cnn3c2nc(NC(c2c(O1)ccc(c2)F)C)cc3
Isomeric SMILES C[C@H]1CNC(=O)c2cnn3c2nc(N[C@@H](c2c(O1)ccc(c2)F)C)cc3
InChI InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1
InChI Key FIKPXCOQUIZNHB-WDEREUQCSA-N
No information available.
Summary of Clinical Use Click here for help
Repotrectinib (TPX-0005) was advanced to a first-in-human dose-escalation Phase 1/2 clinical evaluation in ALK-, ROS1-, or NTRK1-3-rearranged solid and hematological malignancies. Click here to link to ClinicalTrials.gov's full list of TPX-0005 trials. The FDA granted Breakthrough Therapy Designation for repotrectinib in October 2021, as a treatment for NTRK gene fusion +ve advanced solid tumours that have progressed following prior treatment with ≥1 tyrosine kinase inhibitor therapies, and for which there is no other suitable treatment. FDA approval was granted in November 2023 [2], to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer. FDA approval was expanded in June 2024 to include treatment of any patients ≥12 years old with locally advanced/metastatic or unresectable NTRK gene fusion +ve solid tumours, and for which there is no satisfactory alternative therapy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03093116 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Phase 1/Phase 2 Interventional Turning Point Therapeutics, Inc.
NCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Phase 1/Phase 2 Interventional Turning Point Therapeutics, Inc.